In addition, GEPIA analysis demonstrated that TOP2A, SLC2A1, TPX2, and ASPM were upregulated in clinical samples from two major subtypes of NSCLC, i.e. LUAD and LUSC, which stresses the potential relevance of these DEGs in NSCLC development and/or progression. This evidence concerns the gene SLC2A1 and non-small cell lung carcinoma.